Medtronic has announced plans to submit its MiniMed 780G for an expanded indication from the FDA for Type 2 diabetes in the first half of 2025.
Automated insulin delivery (AID) has historically catered to the Type 1 diabetes population, but a number of companies, such as Medtronic, are pursuing expanded indications for their technology. “We’re still largely a Type 1 business,” noted Que Dallara, EVP and president of Medtronic Diabetes. “The clinical data that we’ve generated for Type 2 is extremely good, so we are quite optimistic about the Type 2 opportunity.”
To find out more, CLICK HERE.
